In accordance with its core management principle, the Double Bottom Line(DBL), SK Group has been quantifying the social value(SV) generated by contributing to addressing social issues and pursuing employee happiness in monetary terms since 2019. SK bioscience adopts this SK Group’s method to gauge its own performance. Moving forward, we will continue to actively expand our efforts to create social value through business expansion and ESG management in line with SK Group’s management direction of pursuing both economic and social value.

경제적 가치:기업 경제활동의 최종 결과물로서, 일반적으로 인정되는 기업회계 기준에 의해 공시되는 재무성과

수익

비용

사회적 가치:기업 경제활동울 통해 사회이익을 창출하고 사회훼손 비용을 줄임으로써 창출되는 사회성과

사회창출이익

사회적 비용

SK bioscience provides visible metrics and benchmarks to measure the social value we create. The main measurement areas are indirect economic contributions, environmental performance, and social performance. We embed social value into every process of creating and delivering our products and services. We objectively measure and manage the positive impacts of this value on our society. Additionally, by disclosing our social value measurement formulas, we aim to communicate with various stakeholders and continually improve and refine our performance.

경제간접 기여성과

고용, 납세, 배당 등 기업 활동이 경제에 기여하는 가치

환경성과

친환경 제품 개발 및 생산, 제품 생산 공정에 따른 환경 영향의 (-) 가치

사회성과

제품을 통한 삶의 질 개선, 노동 환경 개선 및 동반성장 활동, 지역사회공헌 활동으로 창출한 가치

Through the business activities, SK bioscience not only generates economic performance for itself but also makes an indirect contribution to the overall economy.

2022년

고용:1,009 억원

배당:0억원

납세:269억원

총 1,278 억원

2023년

고용:1,067억원

배당:0억원

납세:23억원

총 1,090억원

SK bioscience strives to minimize the environmental impacts of the vaccines throughout the entire process of R&D, production, and distribution. We will regularly measure and monitor our environmental performance to continually improve it.

2022년

환경(제품):0 억원

환경(공정):-2억원

총 -2 억원

2023년

환경(제품):0억원

환경(공정):-2억원

총 -2억원

SK bioscience creates social performance by improving the health of customers through vaccines, pursuing the happiness of stakeholders such as employees, and contributing to local communities through corporate philanthropic activities. As we have faced the endemic phase of COVID-19, we are committed to strengthening social and health safety nets and addressing the social issues in the medical and health fields that cannot be solved solely through vaccines. Looking ahead, we will continue to create social value linked to our business by fostering global bio talent who will join us in preparing for the next pandemic.

2022년

사회(삶의 질):384 억원

사회(노동):8억원

사회(동반성장):0억원

사회 공헌:83억원

총 445 억원

2023년

사회(삶의 질):497 억원

사회(노동):21억원

사회(동반성장):0억원

사회 공헌:36억원

총 554 억원